Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: Double-blind comparison with placebo

N. P. Zissis, M. Psaras, Constantine G Lyketsos

Research output: Contribution to journalArticle

Abstract

The therapeutic and unwanted effects of the new long-acting antipsychotic, haloperidol decanoate, were evaluated in 32 stabilized chronic schizophrenics, in a double-blind, randomized, placebo-controlled trial. The follow-up period was 16 weeks and the medication was injected intramuscularly every four weeks. The starting dose was 1.5 ml (equivalent to 150 mg haloperidol) and subsequently was titrated according to the therapeutic and unwanted effects. Deteriorated patients were treated temporarily with active haloperidol tablets. Patients needing more than 3 ml of the d.b. medication or more than 40 mg haloperidol tablets daily, were excluded as failures. Out of the 16 patients included in the active drug group, 11 remained under control, 5 were even improved, very few needed treatment with active haloperidol tablets and none was evaluated as therapeutic failure/ the BPRS and the NOSIE-30 were significantly improved in the haloperidol decanoate group. Patients in the placebo group mostly deteriorated, 13/16 needed additional treatment with active haloperidol tablets and 13/16 were evaluated as therapeutic failures. Less antiparkinson treatment was needed in all patients compared o the pretrial period.

Original languageEnglish (US)
Pages (from-to)650-655
Number of pages6
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume31
Issue number4
StatePublished - 1982
Externally publishedYes

Fingerprint

Haloperidol
Antipsychotic Agents
Placebos
Tablets
Therapeutic Uses
Therapeutics
Randomized Controlled Trials
haloperidol decanoate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{a91915742ad44216a828842470ec14b3,
title = "Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: Double-blind comparison with placebo",
abstract = "The therapeutic and unwanted effects of the new long-acting antipsychotic, haloperidol decanoate, were evaluated in 32 stabilized chronic schizophrenics, in a double-blind, randomized, placebo-controlled trial. The follow-up period was 16 weeks and the medication was injected intramuscularly every four weeks. The starting dose was 1.5 ml (equivalent to 150 mg haloperidol) and subsequently was titrated according to the therapeutic and unwanted effects. Deteriorated patients were treated temporarily with active haloperidol tablets. Patients needing more than 3 ml of the d.b. medication or more than 40 mg haloperidol tablets daily, were excluded as failures. Out of the 16 patients included in the active drug group, 11 remained under control, 5 were even improved, very few needed treatment with active haloperidol tablets and none was evaluated as therapeutic failure/ the BPRS and the NOSIE-30 were significantly improved in the haloperidol decanoate group. Patients in the placebo group mostly deteriorated, 13/16 needed additional treatment with active haloperidol tablets and 13/16 were evaluated as therapeutic failures. Less antiparkinson treatment was needed in all patients compared o the pretrial period.",
author = "Zissis, {N. P.} and M. Psaras and Lyketsos, {Constantine G}",
year = "1982",
language = "English (US)",
volume = "31",
pages = "650--655",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics

T2 - Double-blind comparison with placebo

AU - Zissis, N. P.

AU - Psaras, M.

AU - Lyketsos, Constantine G

PY - 1982

Y1 - 1982

N2 - The therapeutic and unwanted effects of the new long-acting antipsychotic, haloperidol decanoate, were evaluated in 32 stabilized chronic schizophrenics, in a double-blind, randomized, placebo-controlled trial. The follow-up period was 16 weeks and the medication was injected intramuscularly every four weeks. The starting dose was 1.5 ml (equivalent to 150 mg haloperidol) and subsequently was titrated according to the therapeutic and unwanted effects. Deteriorated patients were treated temporarily with active haloperidol tablets. Patients needing more than 3 ml of the d.b. medication or more than 40 mg haloperidol tablets daily, were excluded as failures. Out of the 16 patients included in the active drug group, 11 remained under control, 5 were even improved, very few needed treatment with active haloperidol tablets and none was evaluated as therapeutic failure/ the BPRS and the NOSIE-30 were significantly improved in the haloperidol decanoate group. Patients in the placebo group mostly deteriorated, 13/16 needed additional treatment with active haloperidol tablets and 13/16 were evaluated as therapeutic failures. Less antiparkinson treatment was needed in all patients compared o the pretrial period.

AB - The therapeutic and unwanted effects of the new long-acting antipsychotic, haloperidol decanoate, were evaluated in 32 stabilized chronic schizophrenics, in a double-blind, randomized, placebo-controlled trial. The follow-up period was 16 weeks and the medication was injected intramuscularly every four weeks. The starting dose was 1.5 ml (equivalent to 150 mg haloperidol) and subsequently was titrated according to the therapeutic and unwanted effects. Deteriorated patients were treated temporarily with active haloperidol tablets. Patients needing more than 3 ml of the d.b. medication or more than 40 mg haloperidol tablets daily, were excluded as failures. Out of the 16 patients included in the active drug group, 11 remained under control, 5 were even improved, very few needed treatment with active haloperidol tablets and none was evaluated as therapeutic failure/ the BPRS and the NOSIE-30 were significantly improved in the haloperidol decanoate group. Patients in the placebo group mostly deteriorated, 13/16 needed additional treatment with active haloperidol tablets and 13/16 were evaluated as therapeutic failures. Less antiparkinson treatment was needed in all patients compared o the pretrial period.

UR - http://www.scopus.com/inward/record.url?scp=0020035940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020035940&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020035940

VL - 31

SP - 650

EP - 655

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 4

ER -